Nucala (mepolizumab) logo

Product menu

Head and shoulder image of woman against grey background

Nucala improved CRSwNP symptoms (SNOT‑22) and asthma control (ACQ‑5) in adults with SEA and comorbid CRSwNP1,2

Post-hoc analysis of modified intention-to-treat (mITT) population (SEA patients aged ≥12 years with comorbid NP) in MUSCA.1 MUSCA primary endpoint, change in SGRQ total score from baseline at week 24, was met.3 LS mean change (SE) from baseline in SNOT-22 score of NP patients (n=78) at week 24: Nucala (n=44): -13.7 (2.6); placebo (n=34): -1.9 (3.0). Treatment difference of -11.8 (95%CI, -19.8 to -3.9) (negative values indicates improvement). The effect exceeds the SNOT‑22 minimal clinically important difference (MCID) of 8.9 points.1,5

REALITI-A post hoc analysis at 2-years.2 REALITI-A primary endpoint, rate of clinically significant exacerbations 12-months post-exposure, was met.4 ACQ-5 LS mean score at 24 months in patients with CRSwNP at enrollment, Nucala (n=84): 0.98 vs. Baseline (n=307): 2.72. Statistical significance not calculated.2

The image above is a fictional patient for illustrative purposes.

Nucala (mepolizumab) Indication​

Nucala (mepolizumab) is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. Nucala is also indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.6

Nucala is not reimbursed for CRSwNP in the UK.

Did you know up to 40% of patients with severe asthma suffer from co-morbid CRSwNP?7

For patients with severe asthma and co-morbid CRSwNP, disease burden is higher than those without co-morbidities.8

Find out more about the burden of disease

Burden of disease

Both Severe Eosinophilic Asthma and CRSwNP are often characterised by type 2 inflammation9,10

Nucala blocks IL-5, one of the key cytokines linked to type 2 (T2) inflammation11,12

  • Labelled infographic depicting Eosinophil Proliferation Via IL-5 Signalling
  • Labelled infographic depicting Anti-IL-5 activity by Nucala (mepolizumab)

Dosing & Administration

The recommended dose of Nucala for Severe Eosinophilic Asthma in adults and adolescents aged 12 years and older is 100mg subcutaneously once every 4 weeks. The licensed dose of Nucala in children aged 6 to 11 years old with severe eosinophilic asthma is 40mg subcutaneously once every 4 weeks. In adults for severe CRSwNP the recommended dose of mepolizumab is 100 mg administered subcutaneously once every 4 weeks.6

Image of Nucala (mepolizumab) pre-filled pen

Pre-filled pen (indicated for patients aged 12 years and above for severe eosinophilic asthma. Also indicated for adult patients with severe CRSwNP.)6

Image of Nucala (mepolizumab) pre-filled syringe

Pre-filled syringe (indicated for severe eosinophilic asthma: available in 40mg for children patients aged 6-11 years old, and 100mg for patients aged 12 years and above. Also indicated for adult severe CRSwNP: available in 100mg for adult patients)6

Nucala is for subcutaneous injection only and should be administered by a healthcare professional. Nucala may be self-administered by the patient or administered by a caregiver if their healthcare professional determines that it is appropriate, and the patient or caregiver are trained in injection techniques.6

Find out more about Nucala

Explore Nucala Efficacy Data

Explore Nucala Safety Data

Would you like to learn more about Nucala?

Request a contact

Speak to a representative about Nucala

Stay informed

Get access to patient resources including demo devices, exclusive content on the topics that matter to you and more.

Abbreviations

ACQ, asthma control questionnaire; CI, confidence interval; CRSwNP, chronic rhinosinusitis with nasal polyps; IL-5, interleukin-5; LS (mean), least squares (mean); MCID, minimal clinically important difference; NP, nasal polyps; SE, standard error; SEA, severe eosinophilic asthma; SNOT, sino-nasal outcome test.

References

  1. Howarth P, et al. J Allergy Clin Immunol. 2020;145:1713-15.
  2. Lee et al. AAAAI 2023; poster 48
  3. Chupp GL; Lancet Respir Med. 2017; 5;390-400
  4. Harrison T, et al. Eur Respir J. 2020;56:2000151
  5. GSK Data on File REF-215426
  6. Nucala Summary of Product Characteristics 2026.
  7. Canonica G; Respiratory Medicine. 2020;166;1-5
  8. Bakakos P, et al. J Allergy Clin Immunol Glob. 2024;4(1):100343
  9. Israel, E and Reddel, H. NEJM. 2017;377;965-976
  10. Laidlaw T, et al. JACI; 2021; 9(3):1133-1141
  11. GSK Data on File REF-215426
  12. Bel EH; N Engl J Med. 2014;371;1189-1197
  13. Pelaia C; Front Physiol. 2019;10;1-11
  14. Gevaert P; Int Forum Allergy Rhinol. 2022;12;1413-1423
  15. Trivedi SG; Cellular and Molecular Life Sciences. 2007;64;1269-1289

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellowcard in the Google Play or Apple App Store. Adverse events should also be reported to GSK on 0800 221 441 or UKSafety@gsk.com.

March 2026 | PM-GB-MPL-WCNT-240015 (V1.0)